Cargando…

Predicting early outcomes in patients with intermediate‐ and high‐risk prostate cancer using prostate‐specific membrane antigen positron emission tomography and magnetic resonance imaging

OBJECTIVES: To identify predictors of early oncological outcomes in patients who opt for robot‐assisted laparoscopic radical prostatectomy (RARP) for localized prostate cancer (PCa), including conventional prognostic variables as well as multiparametric magnetic resonance imaging (mpMRI) and prostat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meijer, Dennie, van Leeuwen, Pim J., Donswijk, Maarten L., Boellaard, Thierry N., Schoots, Ivo G., van der Poel, Henk G., Hendrikse, Harry N., Oprea‐Lager, Daniela E., Vis, André N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290881/ https://www.ncbi.nlm.nih.gov/pubmed/34028165 http://dx.doi.org/10.1111/bju.15492

Ejemplares similares

Standardised uptake values as determined on prostate‐specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer
por: Bodar, Yves J.L., et al.
Publicado: (2022)

The oncological characteristics of non‐prostate‐specific membrane antigen (PSMA)‐expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography
por: Veerman, Hans, et al.
Publicado: (2022)

The clinical characteristics of patients with primary non‐prostate‐specific membrane antigen‐expressing prostate cancer on preoperative positron emission tomography/computed tomography
por: Veerman, Hans, et al.
Publicado: (2021)

External Validation of Two Nomograms Developed for (68)Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer (18)F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?
por: Luiting, Henk B., et al.
Publicado: (2021)

Higher Preoperative Maximum Standardised Uptake Values (SUV(max)) Are Associated with Higher Biochemical Recurrence Rates after Robot-Assisted Radical Prostatectomy for [(68)Ga]Ga-PSMA-11 and [(18)F]DCFPyL Positron Emission Tomography/Computed Tomography
por: de Bie, Katelijne C. C., et al.
Publicado: (2023)

Management impact of (18)F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study
por: Meijer, Dennie, et al.
Publicado: (2021)

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer
por: Luining, Wietske I., et al.
Publicado: (2022)

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature
por: Luiting, Henk B., et al.
Publicado: (2019)

Comment on Rosenzweig et al. Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates. J. Pers. Med. 2022, 12, 410
por: Veerman, Hans, et al.
Publicado: (2022)

Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers
por: Luining, Wietske I., et al.
Publicado: (2021)

Distribution of prostate cancer recurrences on gallium‐68 prostate‐specific membrane antigen ((68)Ga‐PSMA) positron‐emission/computed tomography after radical prostatectomy with pathological node‐positive extended lymph node dissection
por: Huits, Thijs H., et al.
Publicado: (2020)

An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More”
por: Hagens, Marinus J., et al.
Publicado: (2022)

Prostate MRI for Improving Personalized Risk Prediction of Incontinence and Surgical Planning: The Role of Membranous Urethral Length Measurements and the Use of 3D Models
por: Boellaard, Thierry N., et al.
Publicado: (2023)

Diagnostic Performance of a Magnetic Resonance Imaging-directed Targeted plus Regional Biopsy Approach in Prostate Cancer Diagnosis: A Systematic Review and Meta-analysis
por: Hagens, Marinus J., et al.
Publicado: (2022)

Active surveillance in intermediate risk prostate cancer: is it safe?
por: Henk, G. van der Poel, et al.
Publicado: (2016)

State of the Art in Prostate-specific Membrane Antigen–targeted Surgery—A Systematic Review
por: Berrens, Anne-Claire, et al.
Publicado: (2023)

Optimization and validation of (18)F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer
por: Luining, Wietske I., et al.
Publicado: (2023)

Abandon the Label of Clinically Insignificant Prostate Cancer
por: Mertens, Laura S., et al.
Publicado: (2022)

Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study
por: Donswijk, Maarten L., et al.
Publicado: (2020)

Detection of prostate cancer with (18)F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial
por: Bodar, Y. J. L., et al.
Publicado: (2020)

Identifying Patients in Whom the Follow-Up Scheme after Robot-Assisted Radical Prostatectomy Could Be Optimized in the First Year after Surgery: Reducing Healthcare Burden
por: Veerman, Hans, et al.
Publicado: (2023)

Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels
por: Meijer, Dennie, et al.
Publicado: (2019)

Prostate-specific Membrane Antigen Positron Emission Tomography, Not Conventional Imaging, Should Be Performed for Primary Staging of High-risk Prostate Cancer: Con
por: van der Poel, Henk
Publicado: (2021)

Prospective analysis of clinically significant prostate cancer detection with [(18)F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study
por: Bodar, Yves J. L., et al.
Publicado: (2021)

Clinical verification of (18)F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer
por: Meijer, Dennie, et al.
Publicado: (2020)

M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting
por: Aluwini, Shafak, et al.
Publicado: (2021)

Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options
por: Zuur, Lotte G., et al.
Publicado: (2023)

Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2020)

Risk‐adapted biopsy decision based on prostate magnetic resonance imaging and prostate‐specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation
por: Schoots, Ivo G., et al.
Publicado: (2020)

Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?
por: Schoots, Ivo G., et al.
Publicado: (2019)

Comparison of (68)Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis
por: Ling, Sui Wai, et al.
Publicado: (2021)

Pelvic lymph-node staging with (18)F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -
por: Jansen, B. H. E., et al.
Publicado: (2020)

Quantitative 3T multiparametric MRI of benign and malignant prostatic tissue in patients with and without local recurrent prostate cancer after external‐beam radiation therapy
por: Dinis Fernandes, Catarina, et al.
Publicado: (2018)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator
por: van Riel, Luigi A.M.J.G., et al.
Publicado: (2022)

MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?
por: Schoots, Ivo G.
Publicado: (2018)

From PROMIS to PRO-MRI in primary prostate cancer diagnosis
por: Schoots, Ivo G., et al.
Publicado: (2017)

Delivering Clinical impacts of the MRI diagnostic pathway in prostate cancer diagnosis
por: Schoots, Ivo G., et al.
Publicado: (2020)

Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting
por: Mehra, Niven, et al.
Publicado: (2023)

Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer
por: Liskamp, C.P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fqatq36cbnhhp57danf47rdpgh